Delving into the Latest Updates on 20-valent neumococcal polysaccharide conjugate vaccine (Xiamen Innovax) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine, Conjugated vaccine

Synonyms-

Target-

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

Pneumococcal InfectionsPneumonia

Inactive Indication-

Originator Organization

Xiamen Innovax Biotech Co., Ltd.

Active Organization

Xiamen Innovax Biotech Co., Ltd.

Jiangsu Kunli Biopharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Primary objective: To evaluate the safety and tolerability of 20-valent pneumococcal polysaccharide conjugate vaccine in healthy people aged 6 weeks and above. Exploratory objective: To explore the immunogenicity of different doses of 20-valent pneumococcal polysaccharide conjugate vaccine in healthy people aged 6 weeks to 5 years.

Start Date11 Feb 2023

Sponsor / Collaborator

Xiamen Innovax Biotech Co., Ltd.

[+1]

100 Clinical Results associated with 20-valent neumococcal polysaccharide conjugate vaccine (Xiamen Innovax)

Login to view more data

100 Translational Medicine associated with 20-valent neumococcal polysaccharide conjugate vaccine (Xiamen Innovax)

Login to view more data

100 Patents (Medical) associated with 20-valent neumococcal polysaccharide conjugate vaccine (Xiamen Innovax)

Login to view more data

100 Deals associated with 20-valent neumococcal polysaccharide conjugate vaccine (Xiamen Innovax)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pneumococcal Infections	Phase 1	CN	Xiamen Innovax Biotech Co., Ltd.	11 Feb 2023
Pneumococcal Infections	Phase 1	CN	Jiangsu Kunli Biopharmaceutical Co., Ltd.	11 Feb 2023
Pneumonia	Phase 1	CN	Jiangsu Kunli Biopharmaceutical Co., Ltd.	11 Feb 2023
Pneumonia	Phase 1	CN	Xiamen Innovax Biotech Co., Ltd.	11 Feb 2023